SEDATION FOR ENDOSCOPY
Sir,-We note with concern the paper by Boldy and coworkers on sedation for endoscopy [1] . In the results section, the authors state that "There were no cardiorespiratory problems in either group." There is no mention of any monitoring used in this study or at what times measurements or observations were made.
Cardiorespiratory changes during sedation for endoscopy are well known. Several studies have shown ECG changes during sedation and insertion of an endoscope [2] [3] [4] [5] , and significant reductions in oxygen tension have been demonstrated after introduction of the endoscope alone, after sedation with a benzodiazepine and after a combination of benzodiazepine and opioid [6] [7] [8] [9] [10] [11] . Midazolam alone has been shown to cause marked respiratory depression [12] .
We have completed a study of cardiorespiratory changes in 20 patients undergoing prolonged endoscopy. Data were recorded continuously by an Atari 1040 ST micro-computer, from ECG lead CM5, a pulse oximeter (Ohmeda Biox 3700), and a non-invasive arterial pressure monitor (Datascope). Sedation was provided by pethidine 25-50 mg and midazolam titrated to effect (mean dose 8 mg). The study commenced before administration of the sedative and continued for the first 1 h of recovery.
Oxygen saturation decreased in all patients (min 82 %, SEM 12.5%), remained so for the duration of the examination and persisted into the recovery period. At the end of the study, saturation had not returned to baseline in 11 patients. An of 42 % was recorded in one patient. Sixteen of the 20 patients developed tachycardia. Ten patients developed supraventricular ectopic beats, ventricular ectopic beats or both. ECG changes resolved during the recovery period. A significant correlation was found between the occurrence of S-T segment depression and hypoxia (r = 0.818, P < 0.00005). No correlation was found between S-T segment depression and arterial pressure, heart rate or rate-pressure product.
From the results of our study and those of others, cardiorespiratory monitoring would appear to be mandatory during upper gastrointestinal endoscopy, especially if opioid analgesics are administered, hypoxia exists already or the patient is in a high risk group.
A. W. MURRAY G. KENNY Sir,-We read with concern the paper by Boldy and colleagues [1] , which seems to highlight much of the misunderstanding concerning the use of i.v. sedation. The authors do not provide details of patient weight, making it difficult to be precise concerning doses used. If we assume that the mean male weight was approximately 70 kg, the mean dose of midazolam used in males was 0.16 mg kg"" 1 . The manufacturer's recommended dose is 0.07 mg kg" 1 for sedation during endoscopy-a dose found to be satisfactory by the second trial from the Hammersmith group [2] (not quoted by Boldy). As midazolam has approximately twice the hypnotic activity of diazepam, it seems unreasonable to compare diazepam 0.15 mg kg" 1 with midazolam 0.16 mg kg" 1 , and hardly surprising that, after endoscopy, patients were more sedated after midazolam.
Five milligrams is the maximum dose of midazolam we use, as the average patient is too profoundly sedated to be cooperative after being given midazolam 10 mg i.v. Bell and colleagues [3, 4] showed significant decreases in oxygen saturation (to less than 80%) during sedation with a benzodiazepine, exacerbated by passage of the gastroscope, and although they used larger doses (means of 6.7 and 6.3 mg) than we would recommend, these were considerably short of the doses of midazolam used by Boldy and colleagues. The addition of opioids to benzodiazepines compounds respiratory depression and hypoxia [5] . We believe that opioid supplementation has no place in sedation for routine upper gastrointestinal endoscopy.
As the peak effect of benzodiazepines given as a single i.v. injection occurs after 2-3 min, "titration" by injecting to a given endpoint cannot take this into account unless this time period is observed between each incremental dose.
The pharmacokinetics of midazolam make it better suited than diazepam to sedation for endoscopy and its superior amnesic properties provide an added clinical benefit. The recent availability of flumazenil, a specific benzodiazepine antagonist, obviates Boldy's assertions that midazolam-induced amnesia is a disadvantage. Antagonism of midazolam 5 mg with flumazenil 0.5 mg i.v. prevents further amnesia, reverses sedation and returns psychomotor variables to normal within 1 min [6] . In all published trials, there has been no clinically significant residual sedation caused by the disparity between the half-lives of the two drugs (57 min cf. 1.3-2.2 h). Of course, when excessive doses of midazolam are used in individual patients, this possibility may be increased.
